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Abstract An unusual case of a 75-year-old man is presented
who had multiple stress fractures due to adult onset
hypophosphatemic osteomalacia, which was the result of
Fanconi syndrome, with light chain cast proximal tubulopathy
due to multiple myeloma. A 75-year-old man presented with
diffuse pain and muscle weakness. He had multiple stress
fractures, low serum phosphate, decreased renal tubular reab-
sorption of phosphate, and normal PTH and FGF23, indicat-
ing adult onset hypophosphatemic osteomalacia. Phosphate
supplements with calcitriol resulted in clinical recovery and
healing of stress fractures. Because of proteinuria, a renal bi-
opsy was performed that revealed Fanconi syndrome with
light chain cast proximal tubulopathy and light kappa chains
were found in serum and urine. A bone biopsy confirmed the
diagnosis of multiple myeloma, and treatment with chemo-
therapy resulted in cytological and clinical recovery.
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Introduction
Diffuse pain is a common complaint of patients in rheumato-
logic practice. It is associated with a variety of diseases, such
as fibromyalgia, thyroid disease, body-wide infection, over-
use, polymyalgia rheumatica, multiple myeloma, and meta-
bolic bone diseases, such as Paget’s disease, hyperparathy-
roidism, and osteomalacia [1]. Medical history, clinical exam-
ination, laboratory examinations, and radiography enable to
make the diagnosis of the most common conditions.
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Unexplained diffuse pain together with increased bone-
specific alkaline phosphatases needs more specific imaging,
such as bone scintigraphy [1]. Paget’s disease is characterized
by typical mono- or poly-osteal involvement. Osteoblastic
metastases show multiple and diffuse focal lesions, while
osteolytic lesions cannot be identified. Osteomalacia is char-
acterized by focal increased uptake at stress locations, such as
around the joints, in the vertebrae, and in the ribs.
Osteomalacia in adults is characterized by bone pain and
muscle weakness. The most frequent cause is vitamin D defi-
ciency in the elderly. Other causes include malabsorption (ce-
liac disease, Crohn’s disease, gastrectomy, gastric bypass,
bowel resection, pancreatitis), impaired hydroxylation of vita-
min D substrate (severe chronic liver disease, renal
o s t eodys t rophy) , an t i - convu l san t t he rapy, and
hypophosphatemic osteomalacia due to phosphate wasting
(oncogenic osteomalacia and Fanconi syndrome) [1].
Diffuse bone pain is themost frequent symptom ofmultiple
myeloma (MM), reported in more than half of patients [2].
Myeloma plasma cells produce receptor activator of the nu-
clear factor kappa B (RANKL), IL-6 and macrophage inflam-
matory protein-1α (MIP1α), that increase bone resorption,
Dickkopf 1 (DKK1), IL-3, IL-7, hepatic growth factor
(HGF), soluble frizzled receptor-like proteins (sFRP) and
sclerostin that decrease bone formation, and TNFα and
Activin A that have mixed effects on bone cells, resulting in
increased vertebral fracture risk in patients with monoclonal
gammopathy of undetermined significance (MGUS) and non-
healing osteolytic lesions with increased risk of pathological
fractures [3–8] (Fig. 1). Renal impairment is found in 20–
40 % of patients, mainly as a result of direct tubular damage
from excess protein load, dehydration, hypercalcemia, and the
use of nephrotoxic medications [8].
In contrast, diffuse bone pain in association with acquired
Fanconi syndrome leading to hypophosphatemic osteomala-
cia is only rarely reported in association with MM [9, 10]. The
pathophysiology of this bone disease is totally different from
the classical osteolytic lesions. Here, monoclonal kappa light
chain paraproteins precipitate as crystal casts in the proximal
renal tubule by binding to Tamm-Horsfall glycoproteins
(THP), causing Fanconi syndrome with renal phosphate
wasting. This results in hypophosphatemia with osteomalacia
with stress fractures (Looser zones) without osteolytic lesions,
and with decreased energy metabolism resulting in muscle
weakness. The clinical course is distinct and characterized a
slow progressive course with an early phase dominated by
metabolic complications [10].
Case summary
A 75-year-old man was referred because of chronic back pain
with increased alkaline phosphatase. The pain was localized in
the vertebral column and radiated to the chest. Physical exam-
ination showed a dorsal hyperkyphosis and restriction of spine
movement. Laboratory results were as follows (normal ranges
in parentheses): serum creatinine 1.55 mg/dL (0.50–1.20),
eGFR 44 mL/min/1.73 m2 (>60), uric acid 1.0 mg/dL (3.4–
7.0), alkaline phosphatase 891 U/L (40–130), serum phospho-
rus 0.46 mmol/L (0.74–1.19), and normal protein
Fig. 1 Schematic representation
of pathophysiologic mechanisms
of bone involvement in MM.
THP Tamm-Horsfall
glycoproteins, PTC proximal
tubular cells, Glom glomerulus,
RANKL receptor activator of the
nuclear factor kappa B, DKK1
dickkopf1, Ocl osteoclast, Obl
osteoblast, MIP1α macrophage
inflammatory protein-1α, HGF
hepatic growth factor, sFRP
soluble frizzled receptor-like
proteins, AKI acute kidney injury,
MGSS monoclonal gammopathy
of skeletal significance
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electrophoresis. CT of the thoracic wall and lumbar spine
showed partially healed fractures of rib 7, 8, 9, and 10 and
an old fracture of the processus transversus L3. MRI of the
pelvis showed aspecific bone remodeling and bone edema in
the right sacrum. The tentative diagnosis of Paget’s disease
was made and zoledronate 5 mg IV with calcium and vitamin
D supplements was given.
Because of increasing diffuse pains and difficulties of
movement, the patient was referred for a second opinion.
He had extreme muscle weakness in shoulders and hips,
and could barely stand up from chair and undress. Lab-
oratory revealed increased alkaline phosphatase of
171 U/L (46 % bone fraction), low phosphate (0.40)
and eGFR (47), and normal calcium, PTH, 25(OH)2D3,
prostate specific antigen, protein electrophoresis, and
TSH. Bone scintigraphy showed multiple uptake zones
in ribs, vertebrae (D6, 7, 8, and 10), right femoral neck,
left acetabulum, left patella, right proximal tibial plateau,
proximal left fibula, right distal tibia, and left calcaneus.
Radiographs showed multiple stress fractures at these
sites, but no osteolytic zones. MRI of the spine indicated
vertebral fractures (D7, 8, and 10) without osteolytic
zones. Bone mineral density was low, with a T-score of
−3.6 in the spine and −2.5 in the total hip. The diagnosis
of adult-onset hypophosphatemic osteomalacia was
made. Further examinations indicated decreased tubular
reabsorption of phosphate (49 %), a positron emission
tomography (PET) revealed no tumors or active granulo-
matous disease, and normal serum value of FGF-23, ex-
cluding tumor-induced osteomalacia syndrome (TIO) as a
cause. Treatment with phosphate, calcitriol, and calcium
supplements resulted in spectacular clinical amelioration
of muscle weakness, normalization of serum phosphate
and alkaline phosphatase, radiographic healing of the
stress fractures within 6 months, and an increase in
BMD of 30 % in the spine and of 9 % in the total hip
after 18 months (T-score of −1.5 and −2.0, respectively).
Because of the deteriorating renal function (eGFR=30) and
no TIO was found, urine analysis was performed showing
proteinuria and glucosuria, and the patient was referred to a
nephrologist. A mixed proteinuria (3 g/d) with excretion of
type kappa monoclonal light chains was found, together with
hypouricemia (1.23 mg/dl), renal glycosuria (696 mg/dl), and
proximal tubular acidosis (urine pH 7 and serum bicarbonate
18.3 meq/l), indicating damage of the proximal tubular cells,
compatible with Fanconi syndrome. An excess of kappa light
chains was also detected in blood with at a concentration of
401 mg/l. A renal biopsy showed normal glomeruli and
intratubular eosinophilic casts and damaged tubular epithelial
cells, suggestive for myeloma cast nephropathy. The diagnosis
of MM was confirmed by the oncologist on a bone marrow
biopsy and treatment with 8 cycles of bortezomib and dexa-
methasone was started. Treatment with phosphate, calcium,
and vitamin D supplements was also continued. Five months
after starting chemotherapy, with three cycles of bortezomib
and dexamethasone, the renal functionwas stabilized (eGFR=
43). A control bone biopsy with immunophenotyping showed
disappearance of monoclonal plasma cells in the bone mar-
row. However, kappa light chains were still present in serum
(102 mg/l) and urine (150 mg/l), with persistent proteinuria
with tubular proteins and TRP was still low (0.61). Although
the patient is now clinically fully recovered without pain and
without complaints of muscle weakness, he still has to take
calcitriol and phosphate supplements, and is further in follow
up by the oncologist.
Discussion
We present a case of sporadic adult-onset hypophosphatemic
osteomalacia due to Fanconi syndrome secondary to light
chain kappa deposition by MM. This is an exceptional case
of MM as diffuse bone pains due to osteolytic lesions and
secondary fractures are the most frequent and typical clinical
manifestation of bone involvement. But in this case, bone pain
was the result of osteomalacia with stress fractures without
osteolytic lesions and accompanied by extreme muscle
weakness.
The clinical challenge to diagnose MM in this patient was
that the initial complaints and laboratory findings directed to
the diagnosis of osteomalacia, and that the clinical symptoms
disappeared and stress fractures healed with phosphate sup-
plements and calcitriol. Interestingly, phosphate and calcitriol
treatment resulted in a major increase of BMD in the spine and
hip, indicating a generalized major correctible mineralization
deficit due to osteomalacia. Only later, the diagnosis of
Fanconi syndrome with MM cast nephropathy lead to the
diagnosis of MM.
Causes of adult onset hypophosphatemic osteomalacia
(AOHO) include increased urinary loss by decreased renal
tubular reabsorption, impaired intestinal absorption, and shifts
of extracellular phosphate into cells [1]. Chronic
hypophosphatemia usually signifies a persistent renal tubular
phosphate-wasting disorder, which can be the result of PTH/
PTHrP-dependent causes (such as hyperparathyroidism) and
PTH/PTHrP–independent causes. This last group includes ex-
cess of FGF23 (such as TIO), intrinsic renal diseases (such as
Fanconi syndrome), other systemic disorders, and drugs/
toxins. Autosomal dominant hypophosphatemic rickets
(ADHR) only rarely presents in adulthood [11]. In this pa-
tient, the diagnosis of AOHO was appropriate, and treat-
ment with phosphate supplements resulted in clinical re-
covery of bone pain and muscle weakness and radiographic
healing of the stress fractures. In this patient, TIO could be
excluded (normal total body PET scan, normal FGF23).
Because of decreased renal function, urine analysis was
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performed, indicating proteinuria, and Fanconi syndrome
was diagnosed.
In patients with Fanconi syndrome, 15/32 presented with
bone pain [9]. Rao reported 2 patients with Fanconi syndrome,
one of whom the initial complaint was muscle weakness [11].
Proximal tubulopathy is the result of monoclonal light chains
that precipitate with Tamm-Horsfall glycoproteins and casts
are formed in the renal tubules. This results in inflammation
and damaging of the tubules, followed by renal insufficiency
if the damage is severe enough [12]. Besides cast nephropathy,
free light chains also cause isolated proximal tubule cell cyto-
toxicity by activation of inflammatory cascades and cause
acute kidney insufficiency [10]. Renal biopsy confirmed cast-
ing and light chains were demonstrated in blood and urine.
The clinical lesson from this patient is that bone disease in
MM is heterogeneous (Fig. 1) and that in sporadic adult
AOHO due to renal phosphate wasting presenting with bone
pain and muscle weakness, and without TIO, the urine should
be controlled for proteinuria and light chains should be
searched in blood and urine. This case is also a nice example
of the concept of monoclonal gammopathy of skeletal
significance (MGSS) [13].
In conclusion, this case report indicates that in adult-onset
sporadic osteomalacia, MM should be part of the differential
diagnosis, when no TIO is detected, even when clinical recov-
ery of bone pain and muscle weakness is achieved with phos-
phate and calcitriol supplements.
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